Sign in
CompletedPhase 4

Olfactory Outcomes of Dupilumab Treatment for Nasal Polyposis

Key facts

Who runs it
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Where
Canada1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 4
People taking part
15 people enrolled
Started
19 Jul 2021
Ended
16 Sept 2026
Type of study
Interventional
Treatments tested
  • Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT]
Record updated
22 September 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Patients older than 18 years old
  • Chronic rhinosinusitis with Nasal Polyps
  • Olfactory loss
  • Clinical indication for treatment with Dupilumab

Who cannot take part

  • Sinonasal malignancies
  • COVID-19 related olfactory loss
  • Patients with olfactory loss from other causes such as:
  • Trauma
  • Idiopathic olfactory loss
  • Use of cocaine
  • Pregnancy

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The study aims to investigate the olfactory TDI score (Threshold, Discrimination, Identification) using the Sniffin' sticks test for patients with chronic rhinosinusitis with nasal polyps (CRSwNP) on dupilumab. Twenty-seven adult patients will be followed up during the treatment with dupilumab on three visits to the Otolaryngology Clinic (Baseline, 3 months and 6 months).

Read full original descriptionShow less

The primary endpoint will be the TDI score. Nasal polyp score, Quality of Olfactory Disorders - negative symptoms (QOD-NS symptom scores), SNOT-22 will be secondary endpoints.

The group in the trial

  • Dupilumab groupTreatment being tested

    Patients with CRSwNP will have an initial dose of 600 mg of dupilumab, and 5 additional doses of 300mg every 4 weeks for 6 months.

    Treatment: Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT]

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
The 'Real World' Olfactory Outcomes Treating Nasal Polyposis With Dupilumab
Record updated
22 September 2026